| top | |
| BRAINLIFE NEWSLETTER | |
Volume 3, Number 22 - 26 June
2004 |
|
|
|
|
|
Contents |
|
|
|
|
| Etiology & Pathogenesis | |
| Overall Management | |
| Prognosis & Outcome | |
| Treatment | |
|
|
|
|
|
|
|
|
|
|
W. K. Rathmell, C. Chmielecki, T.
Van Dyke, M. C. Simon
Models of Von Hippel-Lindau tumor suppressor disease specific activity 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9553 |
|
|
F. Rojo, C. Iglesias, J.
Tabernero, J. Jimenez, S. Rodriguez, J. Bellmunt, S. Ramon, J. Baselga
Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9524 |
|
|
R. Siddiqui, L. Robles Diaz, K. Nafa, N. Kauff, F. Facio, H. Huang, K. Onel, M.
Robson, N. Ellis, K. Offit
TP53 and CHEK2 *1100delC gene mutation in North American families suggestive Li-Fraumeni syndrome: Memorial Sloan-Kettering experience 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9537 |
|
|
J. Spaulding, R. Brekken, L. Robinson, K. Koeneman, B. Mickey, J. Cadeddu, C.
Croft, A. Sagalowsky, N. Ahmad, G. E. Tomlinson
Serum markers of angiogenesis in patients with von Hippel-Lindau Disease 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1033 |
|
|
|
|
|
|
|
|
|
|
|
Lisa M. DeAngelis, MD
Update on Primary Central Nervous System Lymphoma 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Session: An Update on Primary Brain Tumors |
|
| S. Kahl, R. A.
Sala, L. Mengelle, M. Alarcón, L. E. Fein
Application of the Edmonton Functional Assessment Tool (EFAT) in patients with brain metastases (BM) treated only with palliative radiotherapy (PRT) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8054 |
|
|
|
|
|
|
|
|
|
|
|
A. K. Choucair, W. Seiferheld, C.
Ford, J. Hansen, B. Dabbas, C. Schultz, A. Schulsinger, M. Mehta, W. Curran
Long term survivors with glioblastoma multiforme (GBM) treated on RTOG protocols with irradiation and nitrosurea have higher initial expression of Ki-67 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9661 |
|
|
T. Gorlia, R. Stupp, E. A.
Eisenhauer, R. O. Mirimanoff, M. J. Van Den Bent, K. Belanger, D. Lacombe, A.
Allgeier, European Organisation for Research and Treatment of Cancer (EORTC)
Brain And Radiotherapy Groups, National Cancer Institute of Canada (NCIC)
Clinical Trials Group
Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9599 |
|
|
|
|
|
|
|
|
|
|
|
P. P. Breitfeld, J. Anderson, S.
Kao, D. Rodeberg, S. Qualman, S. Wolden, W. Meyer, Children's Oncology Group
Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8513 (Clinical Study) |
|
|
A. Casaco, G. López, R. Fernandez,
L. Diaz, A. Perera, J. Batista, R. Leyva, Y. Peña, J. A. Rodriguez, I. Garcia
Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-Re 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2530 |
|
|
S. Evans, N. Jooma, A. Kabir,
L. Nedzi, E. Zakris, R. Mudad
Seizure prophylaxis in patients with brain metastases from solid tumors: Is phenytoin necessary? 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8186 |
|
| A. E.
Frankel, T. F. Liu, A. M. Thorburn, S. B. Tatter, M. C. Willingham
Recombinant toxin DAB389EGF produces regressions of human glioma xenografts in nude mice 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.3101 |
|
| R.
Goel, S. Gertler, D. J. Stewart, S. Laurie, G. Goss, N. Reaume, C.
Cripps, D. Bedard, A. Rodgers, D. Cutler
Phase I study of temozolomide in conjunction with gemcitabine 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2127 |
|
|
K. Jahnke, A.
Korfel, P. Martus, M. Weller, U. Herrlinger, L. Fischer, E. Thiel
Comparison of high-dose methotrexate (HDMTX) toxicity in elderly and younger patients (pts) with primary central nervous system lymphoma (PCNSL) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8041 |
|
| K.
C. Loh, J. Willert, H. Meltzer, W. Roberts, B. Kerlin, F. Kung, M.
Levy, R. Kadota, A. Yu, M. A. Spear
Temozolomide (TMZ) and radiation (XRT) for aggressive pediatric CNS malignancies 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8566 (Retrospective Study) |
|
|
F. Mayer, S. Koch, E. Malenke, C.
Bokemeyer
Induction of apoptosis by flavopiridol (FP) independent of a cell cycle arrest in germ cell tumor (GCT) cell lines 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.9712 |
|
|
T. E. Merchant, E. N. Kiehna,
R. K. Mulhern, L. E. Kun, S. Wu, X. Xiong, T. Williams, A. Gajjar, F. A.
Boop, R. A. Sanford Results from a phase II trial of conformal radiation therapy for pediatric patients with localized low-grade astrocytoma and quantification of radiation-related CNS effects 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8533 (Clinical Study) |
|
|
S. Ryu, J. Rock, F.-F. Yin, M.
Ajlouni, M. Rosenblum, J. H. Kim
Image-guided radiosurgery for single spinal metastasis 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8033 |
|
|
M. Stevens, A. Rey, N. Bouvet,
C. Ellershaw, J. Sanchez de Toledo, O. Oberlin
SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8515 (Clinical Study) |
|
|
J. Suh, B. Stea, A. Nabid, J.
Kresl, A. Fortin, J. P. Mercier, N. Senzer, E. Chang, J. B. Holz, E. Shaw
Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O2), with or without RSR13 (efaproxiral) in patients with brain metastases: Results of the randomized REACH (RT-009) study 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1534 |
|
|
J. G. Supko, L. Alderson, P. Wen, K. Cassidy, S.
Pace, M. Obrocea, F. Hochberg
Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2039 |
|
|
M. A. Vogelbaum, D. Peereboom, G.
Stevens, G. Barnett, C. Brewer
Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1558 |
|
|
A. L. Yu, A. Batova, R. Gribi, M.
Diccianni, L. Bridgeman, D. Geske, W. London, A. Gilman, F.
Ozkaynak
Antibody-dependent cellular cytotoxicity (ADCC) in COG ANBL0032: A phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell transplant (ASCT) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2582 |
|
|
A. Yung, J. Vredenburgh, T.
Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg,
M. Prados, The Accelerate Brain Cancer Cure Group
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1555 |
|
